Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Interesting lead in the treatment of Ewing`s sarcoma

01.11.2002


Research scientists at INSERM, CNRS and the Institut Curie, in collaboration with physicians, have used a mouse model to demonstrate the efficacy of an innovative therapeutic approach to Ewing`s sarcoma: the combination of human interferon (alpha or beta) and a common anti-tumor agent, ifosfamide.



Their results were published in the November 2002 issue of Oncogene and point to an interesting lead in the development of a less intensive and more effective therapeutic strategy for Ewing`s sarcoma, a severe bone cancer occurring children and adolescents. Before holding out hope, particularly to patients with metastatic disease, whose survival rate is poor, these findings must be confirmed in clinical trials.

For several years now, Jeanne Wietzerbin and her team at the Institut Curie1 have been studying how interferons and other cytokines act on Ewing`s sarcoma. In this new study in mice, they have evaluated the anti-tumor efficacy of interferon-alpha and interferon-beta, two type I interferons, and the combination of one or other of these interferons with ifosfamide (IFO), a widely used anti-cancer agent.


Previous in vitro experiments had demonstrated the antiproliferative activity of these interferons on cell lines derived from Ewing`s sarcoma.

The next logical step was therefore to observe the in vivo activity of the interferons in so-called nude mice (immunodepressed), a relevant animal model of the disease. Ewing sarcoma cells were injected subcutaneously into the nude mice. As the mice are immunodepressed, the cells engraft and engender a solid tumor of human origin which can be used to evaluate the therapeutic potential of innovative treatments.

The administration of interferon-alpha or interferon-beta after injection of the tumor cells impaired engrafting and tumor growth. In addition, interferon-beta, and to a lesser extent interferon-alpha, delayed the growth of established tumors.

Promising synergy

Using this experimental model, the researchers also evaluated the activity of ifosfamide, which blocks DNA replication and hence cell proliferation. It was recently reported that ifosfamide, in conjunction with the chemotherapy conventionally used to treat Ewing`s sarcoma, improves the response in patients hitherto resistant to these treatments.
Jeanne Wietzerbin`s team has therefore pursued its approach in a series of experiments designed to assess the consequences of using interferon-alpha or interferon-beta combined with ifosfamide.

The results in the mouse are convincing. There was marked synergy between the interferon used and the chemotherapeutic agent, resulting in extended survival of the tumor-bearing animals: the necrosis of the tumor tissue was clearly greater than when interferon or ifosfamide was used alone. There was practically no tumor cell division, and the tumor tissue became fibrous and calcified.

It seems that the interferons sensitized the tumor cells to chemotherapy and that ifosfamide sensitized them to the antiproliferative effects of the interferons.

These observations are highly encouraging, especially as survival is poor in the advanced stages of the disease, or when the disease is metastatic at the time of diagnosis, despite intensive treatments combining surgery, chemotherapy and/or radiotherapy. Confirmation of these findings in clinical trials is now needed. The idea is to develop a new therapeutic strategy combining solely interferon and ifosfamide, to be used initially in patients resistant to conventional treatments.

Notes:

1 Jeanne Wietzerbin, director of research at CNRS, heads INSERM Unit 365 "Interferons and cytokines" at the Institut Curie

Reference

"Strong inhibition of Ewing’s sarcoma xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide"
Josiane Sancéau1, Marie-France Poupon2, Olivier Delattre3, Xavier Sastre-Garau4 and Juana Wietzerbin1
Oncogene, vol. 21, pp.7700-09, 31 October 2002

1INSERM U365, Institut Curie, 2CNRS-UMR 147, Institut Curie, 3INSERM U509, Institut Curie, 4Département de Pathologie, Institut Curie, Section Médicale

Press contacts

Institut Curie
Press Relations
Catherine Goupillon
Phone 33(0)1 44 32 40 63
service.presse@curie.fr

Iconography
Cécile Charré
Phone 33(0)1 44 32 40 51
Fax 33(0)1 44 32 41 67

Inserm
Press Office
Céline Goupil
Phone 33(0)1 44 23 60 73
presse@tolbiac.inserm.fr

Séverine Ciancia
Phone 33(0)1 44 23 60 86

CNRS
Press Office
Martine Hasler
Phone 33(0)1 44 96 46 35
martine.hasler@cnrs-dir.fr
Fax 33(0)1 44 96 49 93

Catherine Goupillon | Institut Curie

More articles from Health and Medicine:

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

nachricht A new approach to high insulin levels
18.09.2017 | Schweizerischer Nationalfonds SNF

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>